The FINANCIAL — Takeda Pharmaceuticals Company Limited on October 20 announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), will be presented during the 2015 American College of Gastroenterology (ACG) Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21, and during the United European Gastroenterology Week (UEGW) annual meeting, which takes place in Barcelona, Spain from October 24-28.
Eleven Takeda-sponsored posters, as well as one oral presentation entitled ‘Efficacy of Vedolizumab Maintenance Therapy with and without Continued Immunosuppressant Use in GEMINI 1 and GEMINI 2 (Feagan, Siegel, Melmed, et al.), will be featured during the ACG meeting. Data presented during the UEGW meeting will highlight findings from an analysis of the cost-effectiveness of vedolizumab as a treatment for UC compared with conventional therapy in the United Kingdom, as well as results from a multinational study investigating indicators of suboptimal therapy among UC and CD patients treated with tumor necrosis factor antagonists (TNF-α), according to Takeda.
“At Takeda we strongly believe in the importance of supporting patients around the world with innovative treatment options, and this is why we remain committed to excellence in our scientific exploration of vedolizumab,” said Dr. Michael Smyth, Global Brand Medical Director, Gastroenterology, Takeda Pharmaceuticals. “The extensive study results being presented at these congresses demonstrate that vedolizumab is an important addition to the therapeutic options available for patients living with ulcerative colitis and Crohn’s disease.”
Vedolizumab was approved as a gut-selective humanized monoclonal antibody available in the European Union on May 27, 2014, under the trade name Entyvio (vedolizumab). Entyvio is also available in the United States (U.S.) following U.S. Food and Drug Administration (FDA) approval on May 20, 2014. It is the first and only biologic therapy to be approved in the European Union, as well as in the U.S., simultaneously for the treatment of adults with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha antagonist.